PURE Bioscience develops and commercializes antimicrobial products built on its patented silver dihydrogen citrate (SDC) technology. Company updates center on SDC-based food safety and sanitation applications for food and beverage manufacturing, produce processing, transportation sanitation, and janitorial and consumer cleaning channels.
Recurring news includes fiscal financial results, net product sales trends, distribution partner activity, and product applications such as PURE Control for direct food-contact use and PURE Hard Surface for dairy and beverage membrane treatment. PURE also reports governance and leadership changes tied to its commercial operations and regulatory affairs functions.
PURE Bioscience (PURE) reported fiscal 2026 revenue of $2.318 million, up from the prior year, alongside a wider net loss. For the year ended July 31, 2026, net product sales rose to $2.315 million from $2.198 million. Gross profit increased to $1.326 million from $1.303 million, while operating loss narrowed to $2.083 million from $2.272 million.
Net loss widened to $2.483 million from $2.399 million as net interest expense increased. Loss per share remained $0.02. Operating cash use was $1.97 million versus $2.0 million, and year-end cash increased to $569,000 from $334,000. Current related-party convertible notes reached $3.381 million, including $1.015 million past due. Stockholders’ deficiency widened to $6.399 million from $5.116 million. The company said growth and dairy-industry penetration fell short of expectations, citing slow customer adoption and industry consolidation for the latter.
PURE Bioscience (OTCQB: PURE) reported fiscal Q3 2026 results for the period ended April 30, 2026. Net product sales were $506,000 versus $489,000 a year earlier, with a net loss of $624,000 and loss per share of ($0.01).
For the first nine months, net product sales rose to $1,656,000 from $1,435,000, while net loss was $1,873,000. The company highlighted commercialization of PURE® Clean, growth in transportation applications, and expansion into dairy. CEO Robert Bartlett will retire July 31, 2026, with President Jeff Kitchell succeeding him on August 1, 2026.
PURE Bioscience (OTCQB: PURE) reported fiscal Q2 results for the quarter ended January 31, 2026. Net product sales were $443,000, up $52,000 year-over-year. Net loss was $785,000 for the quarter and $1,249,000 for the six months. The company received USDA Biobased Product Certification for PURE® Clean and expects a Q3 launch and pre-order fulfillment, while advancing dairy in-plant validations, expanding transportation equipment sales, and exploring biomedical partnerships.
PURE Bioscience (OTCQB: PURE) reported fiscal first quarter results for the period ended October 31, 2025. Net product sales were $707,000 versus $555,000 a year earlier, driven by increased end‑user sales. Net loss narrowed to $464,000 from $689,000 year‑over‑year; net loss excluding share‑based compensation was $430,000 versus $632,000. Net loss per share was ($0.00) versus ($0.01) a year earlier. The company reports expanding commercial adoption of its seasonal direct food‑contact solution PURE Control for leafy greens and growth in the transportation channel as SDC‑powered sanitation technology is deployed to major trucking fleets via distribution partners.
PURE Bioscience (OTCQB: PURE) announced leadership promotions effective November 17, 2025. Jeff Kitchell was named President while retaining his role as Corporate Secretary; he has 24 years with the company. Dolana Blount was named Vice President of Operations while retaining her role as Vice President of Regulatory Affairs; she has 27 years with the company. Robert Bartlett will remain CEO and board member but will step down from the President role to focus on CEO duties. Management said the changes aim to strengthen internal talent, operational execution, and strategic development.
PURE Bioscience (OTCQB: PURE) reported fiscal 2025 results for the year ended July 31, 2025, with net product sales of $2,198,000 versus $1,955,000 in fiscal 2024, a $243,000 increase. The company reported a net loss of $2.4 million for FY2025, improved from $3.4 million a year earlier; net loss per share was $0.02 versus $0.03. Net cash used in operations was $2.0 million versus $2.5 million in FY2024. The company reduced personnel, facility and board fees and advanced a membrane treatment for dairy and beverage filtration through pilot trials and new distribution agreements with Hydrite and Bonsai.
PURE Bioscience (OTCQB: PURE) has signed a multi-year distribution agreement with Bonsai, a premium American-made cleaning solutions provider, to expand market access for its patented silver dihydrogen citrate (SDC) antimicrobial products. The partnership enables direct-to-customer sales through Bonsai's online platform.
PURE's flagship product, PURE Hard Surface, is an EPA-registered disinfectant featuring the lowest EPA toxicity rating, no rinse requirement on food contact surfaces, and 99.999% kill times in 30 seconds. The SDC technology works through a dual-action mechanism, deactivating membrane proteins and denaturing DNA of microorganisms.
PURE Bioscience (OTCQB: PURE) reported its fiscal Q2 2025 financial results, showing mixed performance. Net product sales increased to $391,000 in Q2 2025 from $325,000 in Q2 2024, driven by expanded distribution network sales. The company reduced its quarterly net loss to $798,000 from $1,002,000 year-over-year.
For the six-month period, net product sales decreased to $946,000 from $1,043,000, while net loss improved to $1,487,000 from $1,737,000. The company achieved significant cost reductions through decreased personnel costs, professional fees, and share-based compensation.
A major milestone was advancing their dairy membrane solutions from laboratory testing to pilot scale at a California State University and commercial in-plant pilots. The company's non-oxidizing membrane solution for dairy operations demonstrates benefits in water conservation, energy efficiency, fouling removal, and operational cost reduction through minimized Clean-In-Place cycle downtime.